[go: up one dir, main page]

AR015774A1 - Derivados de epotilona 12,13-modificados y sus sales - Google Patents

Derivados de epotilona 12,13-modificados y sus sales

Info

Publication number
AR015774A1
AR015774A1 ARP990101834A ARP990101834A AR015774A1 AR 015774 A1 AR015774 A1 AR 015774A1 AR P990101834 A ARP990101834 A AR P990101834A AR P990101834 A ARP990101834 A AR P990101834A AR 015774 A1 AR015774 A1 AR 015774A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
group
aryl
heterocycle
Prior art date
Application number
ARP990101834A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR015774A1 publication Critical patent/AR015774A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se trata de derivados de epotilona modificados en la posicion 12.13. de formulas: (I) y (II); Q se elige entre los grupos (1); O es alquilo, alquilosustituido, arilo, arilo sustituido, heterociclo, del grupo (2) y L representa O, S, SO2 o NR13 o CR14R15; W es O, o NR16; X es O. S, CHR17 o H2R18; A es O;S; H R19 o R20, o R21; Y se elige entre O; H, H; H,OR22; OR23;OR23,NOR24; H, NOR25; H,NR26R27; NHNR28R29; H, NHNR30R31; O CHR32; en donde OR23, OR23 puedenformar un cetal cíclico; B1 y B2 es H o un grupo OR23, OCOR34, OCONR35R36, NR37R38 O NR39CONR40R41; D es un grupo de NR42R43 o heterociclo; y los demás sesleccionan a partir de carbono, R1, R2, R3 y R4 se seleccionan a partir de H, alquilo inferior; R5, R8, R9, R10 y R11 se seleccionan a partir del grupo queconsiste de H, alquilo, alquilo sustituido, arilo, arilo sustituido, cicloalquilo, heterociclo o heterociclo sustituido; R6 y R7 se seleccionan del grupo queconsiste de H, alquilo, halogeno, nitro ciano, OR47, NR48R49, R50C=O, R17,R18, R22 y R23 se seleccionan a partir del grupo que consiste de H, alquilo yalquilo sustituido; arilo, acilo o arilo sustituido. R20, R21, R24, R25, R26, R28, R30, R32, R33, R34, R35, R36, R37, R39, R40, R41, R42, R47, R48, R50, R51,R52, R53, R54, R56,, R57, R58, R59, y R61 se seleccionan a partir del grupo de H, alquilo, alquilo sustituido, arilo, o arilo sustituido; R12, R13, R16, R27,R31, R38, R43, R44,, R49, R55 y R60 se seleccionan a partir del grupo que consiste en H, alquilo, alquilo sustituido, arilo sustituido, cicloalquilo,heterociclo, R51C=O,R53SO2, hidroxi, O-alquilo o alquilo O sustituido; en donde X es O entonces R16 no es R51C=O, R52OC=O, y R53SO2; y en el cual R44 es ademásamino y formula (B); R14 y R15 se seleccionan a partir del grupo que consiste en H; halogeno, alquilo o alquilo sustituido; R19 se selecciona a partir delgrupo que consiste de H, alquilo, alquilo sustituido, O-alquilo, alquilo O-sustituido, NR54R55, R56C=O; cuando L es O,S, o NR3 entonces R19 no esO-alquilo,
ARP990101834A 1998-04-21 1999-04-21 Derivados de epotilona 12,13-modificados y sus sales AR015774A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8256498P 1998-04-21 1998-04-21

Publications (1)

Publication Number Publication Date
AR015774A1 true AR015774A1 (es) 2001-05-16

Family

ID=22171978

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990101834A AR015774A1 (es) 1998-04-21 1999-04-21 Derivados de epotilona 12,13-modificados y sus sales
ARP990101833A AR015007A1 (es) 1998-04-21 1999-04-21 Compuestos de 12,13-ciclopropano epotilona y sales, solvatos e hidratos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990101833A AR015007A1 (es) 1998-04-21 1999-04-21 Compuestos de 12,13-ciclopropano epotilona y sales, solvatos e hidratos de los mismos

Country Status (17)

Country Link
US (2) US6380395B1 (es)
EP (3) EP1073647B1 (es)
JP (2) JP4476483B2 (es)
CN (1) CN1142923C (es)
AR (2) AR015774A1 (es)
AT (2) ATE340177T1 (es)
AU (2) AU748526B2 (es)
BR (1) BR9909795A (es)
CA (2) CA2329181C (es)
CY (2) CY1105836T1 (es)
DE (2) DE69941083D1 (es)
DK (3) DK1073647T3 (es)
ES (3) ES2273484T3 (es)
PE (1) PE20000460A1 (es)
PT (3) PT1073648E (es)
TR (1) TR200003036T2 (es)
WO (2) WO1999054318A1 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
BR9915940A (pt) * 1998-12-02 2001-09-11 Pfizer Prod Inc Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
EP1165067A4 (en) * 1999-03-29 2002-06-26 Bristol Myers Squibb Co METHOD FOR PREPARING AZYRIDINYLEPOTHIOLONS FROM OXIRANYLEPOTHILONS
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6593115B2 (en) * 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
IL155306A0 (en) 2000-10-13 2003-11-23 Univ Mississippi Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
MXPA03006485A (es) * 2001-01-25 2003-09-22 Bristol Myers Squibb Co Formulacion parenteral que contiene analogos de epotilona.
BRPI0206509B8 (pt) * 2001-01-25 2021-05-25 R Pharm Us Operating Llc processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
JP4633331B2 (ja) * 2001-01-25 2011-02-16 ブリストル−マイヤーズ スクイブ カンパニー 癌治療のためのエポチロン類似体の投与方法
MXPA03007423A (es) 2001-02-20 2003-11-18 Bristol Myers Squibb Co Derivados de epotilona para tratamiento de tumores refractarios.
EP1385529A4 (en) 2001-02-20 2007-05-09 Bristol Myers Squibb Co TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
US7875612B2 (en) * 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
EP1392664A4 (en) * 2001-06-01 2005-01-26 Bristol Myers Squibb Co EPOTHILONE DERIVATIVES
EP2070534A3 (en) 2001-08-23 2009-08-26 Novartis Ag Cyclopropyl and cyclobutyl epothilone analogs
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
DK1483251T3 (da) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
KR20040106547A (ko) * 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2003105828A1 (en) * 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CA2494536C (en) * 2002-07-31 2011-10-04 Mercian Corporation A 12-membered ring macrolide active substance
PT1546152E (pt) * 2002-08-02 2008-03-12 Scripps Research Inst Derivados de epotilona
PT1506203E (pt) * 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN1705662B (zh) 2002-09-23 2011-07-06 布里斯托尔-迈尔斯斯奎布公司 埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构
AU2003279911A1 (en) * 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Therapeutic formulations
HK1080369A1 (zh) * 2002-10-11 2006-04-28 Dana-Farber Cancer Institute, Inc. 用於治疗多发性骨髓瘤的埃博霉素衍生物
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
CA2512867C (en) 2003-01-27 2014-08-26 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
RU2358729C2 (ru) * 2003-10-09 2009-06-20 Козан Байосайенсиз, Инк. Терапевтические композиции
WO2005034964A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US8288557B2 (en) * 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
MX2007005763A (es) * 2004-11-18 2007-07-20 Squibb Bristol Myers Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma.
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
EP1863816B1 (en) 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
BRPI0615354A2 (pt) * 2005-08-19 2011-05-17 Endocyte Inc conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
AR062448A1 (es) * 2006-05-25 2008-11-12 Endocyte Inc Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
PE20080316A1 (es) * 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
WO2008070672A2 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and cpg rich dna
CN101668536A (zh) 2007-02-08 2010-03-10 伊利诺斯大学理事会 用铜氧还蛋白预防癌症的组合物和方法
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) * 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
EP2152717A1 (en) 2007-05-25 2010-02-17 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2690943A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
JP2011500835A (ja) 2007-10-25 2011-01-06 エンドサイト，インコーポレイテッド チューブリシン類および調製プロセス
WO2009146152A2 (en) * 2008-04-04 2009-12-03 Emory University Non-myelosuppressive compounds, pharmaceutical compositions thereof, and methods of treatment
AR071598A1 (es) * 2008-04-24 2010-06-30 Bristol Myers Squibb Co Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
CA2887727A1 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US9725477B2 (en) 2012-11-17 2017-08-08 Beijing Fswelcome Technology Development Co., Ltd Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
MA43178A (fr) * 2015-10-16 2018-09-12 Univ Rice William M Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DK0941227T5 (da) 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
CN1128803C (zh) 1997-02-25 2003-11-26 生物技术研究有限公司(Gbf) 环氧噻嗪酮b－n－氧化物及其制备方法
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PT1001951E (pt) 1997-07-16 2003-02-28 Schering Ag Derivados de tiazolo, processo para a sua preparacao e utilizacao
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
AU753519B2 (en) 1998-02-05 2002-10-17 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
DE50014587D1 (de) 1999-02-18 2007-10-04 Bayer Schering Pharma Ag 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos

Also Published As

Publication number Publication date
US6380395B1 (en) 2002-04-30
EP1589017A2 (en) 2005-10-26
EP1073648A4 (en) 2003-01-02
CN1142923C (zh) 2004-03-24
AU748526B2 (en) 2002-06-06
TR200003036T2 (tr) 2001-01-22
EP1073647B1 (en) 2009-07-08
CA2329181C (en) 2011-02-22
CY1109593T1 (el) 2014-08-13
AU757733B2 (en) 2003-03-06
DE69941083D1 (en) 2009-08-20
EP1073647A1 (en) 2001-02-07
PT1073648E (pt) 2006-12-29
JP2002512238A (ja) 2002-04-23
PT1073647E (pt) 2009-07-17
WO1999054319A1 (en) 1999-10-28
PE20000460A1 (es) 2000-06-09
CN1298398A (zh) 2001-06-06
PT1589017E (pt) 2013-03-04
DK1589017T3 (da) 2013-03-18
EP1073648B1 (en) 2006-09-20
AU3471699A (en) 1999-11-08
CA2329181A1 (en) 1999-10-28
DK1073648T3 (da) 2007-01-08
AR015007A1 (es) 2001-04-11
AU3382799A (en) 1999-11-08
EP1073647A4 (en) 2003-01-02
CA2323609A1 (en) 1999-10-28
JP4476483B2 (ja) 2010-06-09
JP2002512239A (ja) 2002-04-23
ATE435861T1 (de) 2009-07-15
ES2400049T3 (es) 2013-04-05
DE69933287D1 (de) 2006-11-02
ES2327803T3 (es) 2009-11-03
CY1105836T1 (el) 2011-02-02
ES2273484T3 (es) 2007-05-01
BR9909795A (pt) 2000-12-26
DK1073647T3 (da) 2009-11-09
EP1073648A1 (en) 2001-02-07
EP1589017A3 (en) 2009-04-22
DE69933287T2 (de) 2007-05-03
EP1589017B1 (en) 2012-12-05
WO1999054318A1 (en) 1999-10-28
US6399638B1 (en) 2002-06-04
ATE340177T1 (de) 2006-10-15

Similar Documents

Publication Publication Date Title
AR015774A1 (es) Derivados de epotilona 12,13-modificados y sus sales
AR055830A1 (es) Inhibidores de cxcr2
AR016304A1 (es) Compuestos inhibidores de la farnesil proteina transferasa y las composiciones farmaceuticas que los contienen.
AR030432A1 (es) Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.
HRP20030748B1 (hr) Derivati n-arilsulfonilbeta-aminokiselina sa supstituiranom aminometilnom skupinom, metode priređivanja i farmaceutski pripravci koji ih sadržavaju
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
AR045691A1 (es) Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
PE20020722A1 (es) Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano
CO5150230A1 (es) Derivados de azetidina, su preparacion y los medicamentos que los contienen
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
ES2084594T3 (es) Derivados de carboestirilo.
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
AR037881A1 (es) Uso de derivados de oxindol
DK1265862T3 (da) 2-oxo-1-pyrrolidinderivater, fremgangsmåder til fremstilling heraf og deres anvendelse
CO4130326A1 (es) Nuevos derivados de 2-ciano-1,3-diona, composiciones que los contienen, procedimientos para su preparacion y su uso como herbicidas
YU49443B (sh) Derivati benzimidazola, postupci za njihovo pripremanje i primena tih derivata u medicinskoj terapiji, naročito za lečenje ili sprečavanje virusnih infekcija
NO20014529D0 (no) Tetrahydropyranderivater og deres anvendelse som terapautiske midler
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
DK229187D0 (da) 1-substituerede imidazolderivater, 2-thion-tautomere og ikke-toksiske, farmaceutisk acceptable salte deraf
AR051393A1 (es) Adeninas sustituidas y sus usos
ES2184097T3 (es) Nuevos compuestos.
ECSP034561A (es) Derivados puente de piperazina
NO975681L (no) Benzisoxazol- og indazol-derivater som antipsykotiske midler

Legal Events

Date Code Title Description
FB Suspension of granting procedure